Clinical trials: Adult Atopic Dermatitis
Pruritus, Atopic Dermatitis
Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis
This is a two-part, multicenter, randomized, double-blind study to evaluate the efficacy and safety of oral difelikefalin as adjunct therapy to a topical corticosteroid (TCS) for moderate-to-severe pruritus in adult subjects with…
- Trial name
- KIND-1 (NCT05387707)
- Testing
- difelikefalin 0.25 mg, difelikefalin 0.5 mg, TCS Cream
- Where
- 61 sites in United States
- Volunteers
- 287 people
- Sponsor
- Cara Therapeutics, Inc.
Dermatitis, Atopic
Safety and Efficacy of AN2728 Topical Ointment, 2% in Children, Adolescents, and Adults (Aged 2 Years and Older) With Atopic Dermatitis
The purpose of this study is to investigate the safety and efficacy of AN2728 Topical Ointment, 2% in children, adolescents, and adults (ages 2 years and older) with atopic dermatitis.
- Trial name
- NCT02118792
- Testing
- AN2728 Topical Ointment, 2%, Matching vehicle control
- Where
- United States
- Volunteers
- 764 people
- Sponsor
- Pfizer
Dermatitis Atopic
An Open-label, DDI Study to Investigate the Effects of Amlitelimab on the PK of Selected Cytochrome P450 Substrates
This is an open-label, single group, 2-period, Phase 1, single-sequence study. The study duration will be up to 342 days. The treatment period will be up to Week 29, where Week 29 is defined as End of Treatment (last amlitelimab…
- Trial name
- NCT06686628
- Testing
- Amlitelimab, Midazolam, Caffeine
- Where
- Germany
- Volunteers
- 23 people
- Sponsor
- Sanofi
Dermatitis, Atopic
Evaluation of 611 in Chinese Adult Patients With Moderate-to-Severe Atopic Dermatitis
The primary objective of the study was to evaluate the safety and tolerability of 611 in chinese adults with moderate to severe atopic dermatitis.
- Trial name
- NCT05641558
- Testing
- 611 150mg, 611 300mg, 611 600mg
- Where
- 5 sites in China
- Volunteers
- 24 people
- Sponsor
- Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Mild to Moderate Atopic Dermatitis
Evaluation of the Effect of the Product RV4660C CY0203 on Clinical, Biometrological and Biological Parameters in Adults With Mild to Moderate Atopic Dermatitis, an Exploratory Study
In this exploratory study, we assessed the efficacy of a cosmetic product in adults suffering from mild to moderate atopic dermatitis. This exploratory study has been conducted as a monocentric non randomized study.
- Trial name
- NCT07166497
- Testing
- Cosmetic product RV4660C CY0203
- Where
- France
- Volunteers
- 21 people
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis, Dermatitis, Atopic
Topical GW842470X In Adults Patients With Moderate Atopic Dermatitis
The purpose of this study is to investigate the clinical efficacy of 3% (w/w) GW842470X cream applied to involved skin of adult patients with moderate atopic dermatitis using the Eczema Area Severity Index (EASI) assessment of…
- Trial name
- NCT00354510
- Testing
- GW842470X cream
- Where
- 13 sites in Germany, Netherlands
- Volunteers
- 190 people
- Sponsor
- GlaxoSmithKline
Atopic Dermatitis
Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic Dermatitis
This is a phase 2, multi-center, randomized, placebo-controlled, double-blind, parallel-group, dose-ranging study, conducted in subjects with moderate-to-severe atopic dermatitis.
- Trial name
- NCT05048056
- Testing
- AK120
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 79 people
- Sponsor
- Akesobio Australia Pty Ltd
Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema
Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
A Phase 2b study investigating the efficacy of zabalafin in people with mild to moderate atopic dermatitis (eczema).
- Conditions
- Atopic Dermatitis (Eczema), Atopic Dermatitis Eczema, Atopic Dermatitis, Atopic Dermatitis (AD)
- Trial name
- CLEAR-AD1 (NCT06855745)
- Testing
- zabalafin
- Where
- 12 sites in Australia
- Volunteers
- 72 people
- Sponsor
- Alphyn Biologics
Normal Volunteers, Atopic Dermatitis (AD)
Safety, Tolerability and PK of ATTO-3712 in Healthy Volunteers and Patients With Atopic Dermatitis
The goal of this clinical trial is to assess the safety, tolerability, and pharmacokinetics of ATTO-3712 in healthy adults and patients with atopic dermatitis.
- Conditions
- Normal Volunteers, Atopic Dermatitis (AD), Atopic Eczema, Atopic Eczema/Dermatitis (Non-Specific)
- Trial name
- NCT07205081
- Testing
- ATTO-3712
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Attovia Therapeutics Inc
Atopic Dermatitis, Atopic Dermatitis Eczema
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
The purpose of this study is to evaluate the efficacy and safety of different dose regimens of IMG-007, compared to placebo.
- Conditions
- Atopic Dermatitis, Atopic Dermatitis Eczema, Eczema
- Trial name
- ADAPTIVE (NCT07037901)
- Testing
- IMG-007
- Where
- 30 sites in United States, Australia and 2 more
- Volunteers
- 405 people
- Sponsor
- Inmagene LLC
Atopic Dermatitis
A Study to Evaluate Safety of Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis
The objective of this study is to assess the safety of upadacitinib combined with topical corticosteroids (TCS) in adolescent and adult participants in Japan with moderate to severe atopic dermatitis (AD) who are candidates for…
- Trial name
- Rising Up (NCT03661138)
- Testing
- Upadacitinib, Topical Corticosteroids (TCS)
- Where
- 43 sites in Japan
- Volunteers
- 272 people
- Sponsor
- AbbVie
Atopic Dermatitis
Proof of Concept Study of Rilzabrutinib in Adult Patients With Moderate-to-severe Atopic Dermatitis
This was a parallel treatment, Phase 2, double-blind, 2-arm, placebo-controlled study with 2 staggered cohorts (2 arms in each cohort) to evaluate the efficacy and safety of rilzabrutinib in adult participants (aged at least 18…
- Trial name
- NCT05018806
- Testing
- Rilzabrutinib
- Where
- 31 sites in United States, Canada and 5 more
- Volunteers
- 124 people
- Sponsor
- Sanofi
Atopic Dermatitis
Phase II Clinical Study to Evaluate the Efficacy and Safety of VC005 in Adult Subjects With Mild to Moderate Atopic Dermatitis
A multicenter, randomized, double-blind, vehicle controlled phase II clinical study
- Trial name
- NCT06891040
- Testing
- VC005 groups
- Where
- China
- Volunteers
- 118 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
Atopic Dermatitis Eczema
Safety and Efficacy Study of EVO101 Topical Cream in Atopic Dermatitis
This is a Phase 2a safety and efficacy study of EVO101 for the treatment of adults with atopic dermatitis
- Trial name
- NCT05579899
- Testing
- EVO101
- Where
- 21 sites in United States
- Volunteers
- 119 people
- Sponsor
- Evommune, Inc.
Hand Eczema
Topical Ruxolitinib Evaluation in Chronic Hand Eczema
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CHE) and moderate to severe disease activity (Investigator's Global Assessement…
- Trial name
- NCT05906628
- Testing
- Ruxolitinib cream, Vehicle
- Where
- 36 sites in United States, Canada and 2 more
- Volunteers
- 186 people
- Sponsor
- Incyte Corporation
Atopic Dermatitis, Healthy
Assessment of Clinical, Biological and Biometrological Parameters in Adults Subjects With Atopic Dermatitis
In most recent years, the gut microbiome has been highlighted as a key player in the control of organs distant from the gut. Indeed, studies have raised evidence that gut microbiota exerts a control on various diseases including…
- Trial name
- NCT07017348
- Testing
- Clinical assessments, Biometrological measurements, Biological sampling
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Dermo Cosmetique
Atopic Dermatitis
A Clinical Trial to Evaluate the Safety and Efficacy of a Moisturizer Body Lotion in Adults of Atopic Dermatitis.
This study will evaluate the safety and efficacy of a moisturizer body lotion: the study aims to determine the tolerance of this product by the study population, and its effects on atopic dermatitis condition, skin hydration…
- Trial name
- NCT05062213
- Testing
- Moisturizer Body Lotion
- Where
- Brazil
- Volunteers
- 34 people
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)
Atopic Dermatitis (AD)
A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis
This study is an Ic/II phase clinical trial conducted in Chinese subjects with moderate to severe atopic dermatitis. The phase Ic study is a randomized, open label, parallel group design, mainly evaluating the safety and…
- Trial name
- NCT06931990
- Testing
- LT-002-158 tablets
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.
Atopic Dermatitis
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis (AD). The purpose of the study is to test a new tablet (LEO 152020) to see if it improves AD and what the side effects are…
- Trial name
- NCT05117060
- Testing
- LEO 152020 tablet
- Where
- 45 sites in United States, Australia and 6 more
- Volunteers
- 216 people
- Sponsor
- JW Pharmaceutical
Moderate to Severe Atopic Dermatitis
Efficacy and Safety Clinical Study of VC005 Tablets in Adult Patients With Moderate to Severe Atopic Dermatitis
This clinical trial is a multicenter, randomized, double-blind, controlled phase II clinical study.
- Trial name
- NCT05997927
- Testing
- VC005 tablets
- Where
- China
- Volunteers
- 149 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD